Loading
institutionsInstitution
Instituto Português de Oncologia do Porto Francisco Gentil
Northern Portugal's dedicated cancer hospital, an OECI-accredited comprehensive cancer centre known for hereditary cancer genetics and epigenetic biomarkers.
Also called: IPO PortoIPO-Porto
Overview
IPO Porto is the public cancer hospital and research institute for northern Portugal and holds OECI accreditation as a comprehensive cancer centre. Its cancer genetics department under Manuel Teixeira is a national reference for hereditary breast, ovarian and gastric cancer syndromes, and Rui Henrique and Carmen Jerónimo's epigenetics group developed DNA methylation biomarkers for prostate and other cancers. The hospital delivers surgery, radiotherapy including brachytherapy, medical oncology, haematology with transplantation and CAR-T, and paediatric oncology, and runs a large tumour bank and a portfolio of academic and industry trials. It coordinates the Porto Comprehensive Cancer Center with the University of Porto's i3S institute.
Location
Porto, PT
Type
cancer center · Universidade do Porto
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#161 · 32 points (0 Newsweek + 0 NCI + 32 from 16 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-15.
Matched to IPO Porto, including child institutions. 172 works · 1,084 citations · 76% open access · 6% clinical trials · 6% reviews.
Oncology works per year
412022
402023
432024
302025
182026
Most works
- Mário Dinis‐Ribeiro19 works
- Júlio Oliveira9 works
- Lúcio Lara Santos8 works
- María José Bento8 works
- Rui Medeiros7 works
- Diogo Libânio5 works
- Cármen Jerónimo5 works
- Manuel R. Teixeira5 works
- Filipa Fontes5 works
- Nuno Lunet5 works
Most cited
- Hereditary cancer genetics
- Epigenetic biomarkers
- Haematology and transplantation
- Radiotherapy and brachytherapy
- Porto Comprehensive Cancer Center
Similar pages
- PersonMaria Margarida Torres de Ornelas
Shares Instituto Português de Oncologia de Coimbra Francisco Gentil, Instituto Português de Oncologia de Lisboa Francisco Gentil, Organisation of European Cancer Institutes.
- IdeaOncology teams order germline tests; tele-genetic counsellors handle the results
Shares Inherited risk is mostly unidentified, Germline (hereditary) testing, Ovarian cancer, HR-positive / HER2-negative breast cancer.
- IdeaPopulation germline screening for hereditary cancer genes with cascade testing
Shares Inherited risk is mostly unidentified, BRCA1 / BRCA2 (HRD), Germline (hereditary) testing, Ovarian cancer.
- PersonRachel Michaelson-Cohen
Shares Inherited risk is mostly unidentified, BRCA1 / BRCA2 (HRD), Germline (hereditary) testing, Ovarian cancer.
- IdeaGo back to families of women who died of ovarian cancer and offer BRCA testing
Shares Inherited risk is mostly unidentified, BRCA1 / BRCA2 (HRD), Germline (hereditary) testing, Ovarian cancer.
- PersonEitan Friedman
Shares Inherited risk is mostly unidentified, BRCA1 / BRCA2 (HRD), Germline (hereditary) testing, Ovarian cancer.
- PersonEphrat Levy-Lahad
Shares Inherited risk is mostly unidentified, BRCA1 / BRCA2 (HRD), Germline (hereditary) testing, Ovarian cancer.
- Key paperFounder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer
Shares Inherited risk is mostly unidentified, BRCA1 / BRCA2 (HRD), Germline (hereditary) testing, Ovarian cancer.